$BVXV
Biondvax Pharmaceuticals Ltd
PRICE
$1.17 β²0.429%
Last Close
VOLUME
32,904
DAY RANGE
1.13 - 1.19
52 WEEK
1 - 4.19
Key Metrics
Market Cap
13.28 M
Beta
1.37
Avg. Volume
41.15 K
Shares Outstanding
11.35 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trialβs primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.
CEO: Ron Babecoff
Website: www.biondvax.com
HQ: Weizmann Science Park Po Box 4143 14 Einstein Street, 7403618 Ness Ziona
Related News